Significant Funding Advances in Gastroesophageal Cancer Treatment
The DeGregorio Family Foundation, supported by the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, recently announced a grant of $100,000 aimed at combating the challenges posed by immune cell suppression in gastroesophageal cancer.
About the Grant and Its Recipient
This grant, dedicated to the memory of Michael F. Price, a respected value investor and philanthropist, has been awarded to Dr. Zheng Chen, a passionate researcher and Assistant Professor of Surgery at the University of Miami Miller School of Medicine. Dr. Chen’s pivotal work is expected to make a significant impact in a field where innovative solutions are urgently needed.
Understanding the Challenge of Gastric Cancer
Gastric cancer remains one of the most lethal forms of cancer worldwide. With a five-year survival rate of merely 32 percent, the prognosis for patients diagnosed at later stages is particularly grim. While immunotherapy has emerged as a potent weapon against various cancers, its efficacy in treating gastroesophageal cancer has been disappointingly low, with only about 30 percent of patients showing any positive response.
Dr. Chen's Groundbreaking Research
Dr. Chen's research is focused on identifying and utilizing FDA-approved drugs that can specifically target the unique molecular features found in immune desert-type gastric cancer. This particular type of tumor is characterized by a scarcity of T cells and a weakened immune response, making it a significant area of concern for researchers.
A Word from Dr. Chen
"Receiving this award is an incredible honor and a critical step towards translating our research into a meaningful clinical impact for patients with gastroesophageal cancer," Dr. Chen remarked. "The resources provided through this award enable us to move closer to developing new treatment options tailored for patients who face limited therapeutic alternatives."
Enhancing Immunotherapy Possibilities
Lynn DeGregorio, President and Founder of the DeGregorio Family Foundation, expressed confidence in the potential of the grant, stating, "Enhancing immunotherapy in gastroesophageal cancer is a remarkable opportunity. We are truly excited about the chances this funding provides for essential advancements in this field."
The Impact of the DeGregorio Family Foundation
Founded in 2006, the DeGregorio Family Foundation has raised over $12 million to fund pioneering research initiatives focused on curing gastric and esophageal cancers. This foundation stands out as the only public entity dedicated to supporting research grants specifically designed to tackle these two particular cancer types.
How to Support the Cause
The foundation encourages contributions to continue its mission of supporting critical research efforts. For those looking to get involved, they provide options to contribute financially to this important work.
Frequently Asked Questions
1. What is the main focus of the DeGregorio Family Foundation's recent grant?
The grant primarily aims to explore and enhance immunotherapy treatments for gastroesophageal cancer.
2. Who is the recipient of the $100,000 grant?
The grant has been awarded to Dr. Zheng Chen, an Assistant Professor of Surgery.
3. How common is gastric cancer, and what is the survival rate?
Gastric cancer is a leading cause of cancer-related deaths globally, with a five-year survival rate of about 32 percent.
4. What challenges does immunotherapy face in treating gastric cancer?
The response rates for immunotherapy in gastric cancer are low, especially in immune desert-type tumors with limited immune response.
5. What is the history of the DeGregorio Family Foundation?
Founded in 2006, the foundation was established following the loss of a family member to stomach cancer and has since raised significant funds for research.
